Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company‚Äôs equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Reported
DateTime
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportFiling
2023-02-14
1:00 pm
Purchase
13GRubius Therapeutics, Inc.
RUBY
Flagship VentureLabs IV LLC38,606,526
42.7%
38,606,526increase
(New Position)
View
2022-10-17
4:32 pm
Purchase
13DAxcella Health Inc.
AXLA
Flagship VentureLabs IV LLC29,251,545
39.8%
10,383,760increase
(+55.03%)
View
2022-09-23
4:31 pm
Unchanged
13DAxcella Health Inc.
AXLA
Flagship VentureLabs IV LLC18,867,785
35.8%
0
(Unchanged)
View
2022-07-07
5:00 pm
Purchase
13DSeres Therapeutics, Inc.
MCRB
Flagship VentureLabs IV LLC23,493,063
18.9%
8,443,072increase
(+56.10%)
View
2022-03-18
08:30 am
Purchase
13DAxcella Health Inc.
AXLA
Flagship VentureLabs IV LLC18,867,785
36.4%
6,319,371increase
(+50.36%)
View
2020-11-25
4:30 pm
Sale
13DSeres Therapeutics, Inc.
MCRB
Flagship VentureLabs IV LLC15,049,991
16.5%
-6,596,914decrease
(-30.48%)
View
2020-05-20
5:00 pm
Purchase
13DAxcella Health Inc.
AXLA
Flagship VentureLabs IV LLC12,548,414
35%
3,800,000increase
(+43.44%)
View
2019-06-28
4:30 pm
Purchase
13DSeres Therapeutics, Inc.
MCRB
Flagship VentureLabs IV LLC21,646,905
30.96%
21,646,905increase
(New Position)
View
2019-05-23
4:16 pm
Purchase
13DAxcella Health Inc.
AXLA
Flagship VentureLabs IV LLC8,748,414
38.1%
8,748,414increase
(New Position)
View